CASE-BASED ROUNDTABLE

Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

Latest Articles

Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma

Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma

November 12, 2026

During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.

Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL

Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL

November 10, 2026

Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.

Comparing Treatment Approaches in Second-Line Metastatic ccRCC

Comparing Treatment Approaches in Second-Line Metastatic ccRCC

November 09, 2026

During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.

LITESPARK-011 Raises Questions About RCC Treatment Sequencing

LITESPARK-011 Raises Questions About RCC Treatment Sequencing

November 06, 2026

Oncologists discuss LITESPARK-011 findings and the potential role of belzutifan plus lenvatinib in second-line advanced renal cell carcinoma treatment and sequencing.

Maintenance Lurbinectedin Raises Stakes of Checkpoint Choice in ES-SCLC

Maintenance Lurbinectedin Raises Stakes of Checkpoint Choice in ES-SCLC

November 05, 2026

During a live event, Wade T. Iams, MD, discussed the issues facing oncologists selecting treatment for patients with extensive-stage small cell lung cancer.

Choosing CLL Therapy Around Molecular Risk, Comorbidities, and Patient Preference

Choosing CLL Therapy Around Molecular Risk, Comorbidities, and Patient Preference

October 22, 2026

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma

Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma

October 21, 2026

During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.

Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma

Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma

October 20, 2026

During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.

Considering the Role of Tivozanib After Prior ICI-Based Therapy in RCC

Considering the Role of Tivozanib After Prior ICI-Based Therapy in RCC

October 16, 2026

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.

Neoadjuvant T-DXd Clouds Residual Disease Decisions in HER2+ Breast Cancer

Neoadjuvant T-DXd Clouds Residual Disease Decisions in HER2+ Breast Cancer

October 15, 2026

During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.

Insurance Hurdles Complicate Febrile Neutropenia Prevention in ES-SCLC

Insurance Hurdles Complicate Febrile Neutropenia Prevention in ES-SCLC

October 14, 2026

During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.

How Disease Burden Shapes First-Line RCC Treatment Selection

How Disease Burden Shapes First-Line RCC Treatment Selection

October 13, 2026

Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.

Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia

Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia

October 08, 2026

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.

Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma

Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma

October 05, 2026

Luciano Costa, MD, PhD, explains the findings from a competing risk analysis of the MajesTEC-3 trial linking survival to reduced myeloma progression.

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

September 28, 2026

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

View a specific disease type